Inclusion Criteria:

- histologically confirmed oestrogen receptor negative primary breast cancer, tumour
stage T2-3, N0-2, M0. Eligible for surgery, WHO performance score 0-1.

Exclusion Criteria:

- any prior anticancer therapy including gefitinib (Iressa®), epirubicin
(Farmorubicin™), or cyclophosphamide, distant metastases or bilateral breast cancer,
any evidence of clinically active interstitial lung disease , other co-existing
malignancies or malignancies diagnosed within the last 5 years with the exception of
basal cell carcinoma or cervical cancer in situ, pregnancy or breastfeeding